02.04.2012 - Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV
02 Apr 2012
02.04.2012 Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV
Shionogi Limited. Registered in England and Wales No. 07945432. Registered office: 33 Kingsway. London WC2B 6UF, UK.
Report Side Effect
Just to let you know, you are now moving to another website this is not under our control and Shionogi Limited is not responsible for its contents.